Skip to content

Carpal Bone Erosion in Rheumatoid Arthritis :Diagnostic Value

Carpal Bone Erosion in Rheumatoid Arthritis :Diagnostic Value

Status
Not yet recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06562049
Enrollment
110
Registered
2024-08-20
Start date
2024-08-15
Completion date
2025-10-01
Last updated
2024-08-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid Arthritis

Brief summary

Rheumatoid arthritis (RA) is a systemic inflammatory disease characterized by proliferative hyper vascularized synovitis which primarily affects synovial joints. Synovium of bursa; tendon sheaths; attachment sites of cartilage, ligament, and tendons to the bone; soft tissue; and bones can be mentioned among the other areas under influence of RA. Changes happen to be symmetrical and may present as fusiform soft tissue swelling, regional osteoporosis, marginal-central erosions, cartilage damage, joint destruction, narrowing of joint space and fibrous ankyloses. Wrist, metacarpophalangeal and metatarsophalangeal joints are the first sites to be affected .Over the past few years, an increasing number of rheumatologists have started to use US in the clinical setting of the early arthritis clinic. While US allows for an accurate and non-invasive multisite assessment of joint involvement in patients with RA, time for US examination is not infinite

Interventions

musculoskeletal ultrasound on both hands

Sponsors

Sohag University
Lead SponsorOTHER

Study design

Observational model
OTHER
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years

Inclusion criteria

* 1\. RA patients fulfilled the 2010 American College of Rheumatoid Arthritis classification criteria.\[8\] 2. SLE patients fulfilled the 2019 ACR\\EULAR classification criteria for SLE.\[9\] 3. Age above 18 years old. 4. Patient cooperative and can answer questions. 5. Patients who are able and willing to give written informed consent.

Exclusion criteria

* 1\. Age below 18 years and above 60 years. 2. Uncooperative patients. 3. Patient not able and willing to give written informed consent.

Design outcomes

Primary

MeasureTime frameDescription
bone erosionmax 1 yearerosions in carpal bones and MCP 2,5 in both hands

Countries

Egypt

Contacts

Primary Contactabeer A abdelaal, Resident
abeer_abdelaal_post@med.sohag.edu.eg01206290115
Backup Contactahmed M mahrous, Professor

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026